Outcomes of cardiac surgery in Indigenous Australians

Sam J Lehman, Robert A Baker, Philip E Aylward, John L Knight and Derek P Chew
Med J Aust 2009; 190 (10): 588-593. || doi: 10.5694/j.1326-5377.2009.tb02573.x
Published online: 18 May 2009


Objective: To describe baseline characteristics, operative events and late mortality among Indigenous Australians undergoing cardiac surgery.

Design, setting and participants: Prospective study of consecutive patients undergoing cardiac surgery at Flinders Medical Centre in Adelaide between January 2000 and December 2005.

Main outcome measures: Operative (30-day) mortality and late mortality after cardiac surgery.

Results: Of 2635 patients undergoing cardiac surgery, 283 (10.7%) were Indigenous. Indigenous patients were substantially younger than non-Indigenous patients (mean, 47 [SD, 14] years v 65 [SD, 12] years; P = 0.001) and were more likely to have diabetes (39.6% v 27.3%; P = 0.001), renal dysfunction (3.2% v 1.2%; P = 0.009), and valvular surgery (53.0% v 23.1%; P < 0.001). There was a non-significant trend toward excess operative mortality in Indigenous patients (Indigenous 2.5% v non-Indigenous 1.3%; hazard ratio [HR], 1.67 [95% CI, 0.74–3.75]). But in the under-55-years age cohort, the difference between the two groups was highly significant (Indigenous 3.3% v non-Indigenous 0.4%; HR, 7.99 [95% CI, 1.66–38.50]), even after adjustment for euroSCORE (the European System for Cardiac Operative Risk Evaluation). Survival at 1 and 5 years was 94.0% and 80.6%, respectively, for Indigenous patients compared with 96.7% and 87.7%, respectively, for non-Indigenous patients. There was an excess in euroSCORE-adjusted mortality in the Indigenous cohort overall (HR, 1.46 [95% CI, 1.03–2.07]) that strengthened when restricted to the under-55-years cohort (HR, 6.9 [95% CI, 1.42–33.5]).

Conclusion: Indigenous Australians present for cardiac surgery nearly 20 years earlier than non-Indigenous Australians and experience excess age-stratified operative and late mortality.

Cardiovascular disease is more prevalent among Indigenous Australians than non-Indigenous Australians, and Indigenous Australians present for cardiac surgery about 20 years earlier, on average. This is likely to be due both to higher rates of traditional cardiovascular risk factors and to persistence of rheumatic heart disease.1-4 In addition to differences between Indigenous and non-Indigenous Australians in disease prevalence, there is evidence of disparity in outcomes after acute cardiovascular events such as myocardial infarction.5,6 While cardiac surgery is highly effective, outcomes for Indigenous patients may be less favourable, owing to more extensive disease at the time of presentation, a higher prevalence of cardiovascular risk factors, difficulty accessing ongoing medical care, and higher mortality from non-cardiovascular causes.

The aim of our study was to explore whether the increased mortality associated with coronary heart disease in Indigenous Australians is normalised after cardiac surgery.

Baseline data and definitions

A structured form was completed for each patient on hospital admission to record age, sex, self-reported Indigenous status (including Torres Strait Islander), cardiovascular risk factors and medical history.

Hypertension was defined by either a documented history of hypertension diagnosed and treated with medication, diet and/or exercise; or a measured systolic blood pressure of > 140 mmHg or diastolic pressure of > 90 mmHg on at least two occasions.

Hyperlipidaemia was defined by a history of hypercholesterolaemia diagnosed by a physician and/or a serum cholesterol level > 5.0 mmol/L.

Diabetes was defined by a previous physician diagnosis or treatment with hypoglycaemic medication.

The European System for Cardiac Operative Risk Evaluation (euroSCORE) is a widely used model for predicting 30-day mortality in patients undergoing cardiac surgery7 (the higher the euroSCORE, the higher the predicted operative mortality). It was developed from outcomes in 128 European centres and has been validated in European, Japanese, and North American populations.8-12 Although the euroSCORE model has previously been shown to overestimate operative mortality in an Australian population, it does provide sufficient discrimination between strata of risk.13,14 Using standard component definitions, we calculated the logistic euroSCORE for all patients preoperatively (Box 1).7

Preoperative renal dysfunction was defined by a serum creatinine level > 200 μmol/L.

Preoperative neurological impairment was defined by a condition affecting ambulation or daily functioning.

Critical preoperative state was defined by preoperative ventricular arrhythmia, acute renal failure, or the need for resuscitation or haemodynamic support.

An assessment of left ventricular systolic function was obtained either by echocardiography or left ventriculography and classified, on the basis of ejection fraction (EF), as moderate systolic impairment (EF, 30%–50%) or severe systolic impairment (EF < 30%).

Statistical analysis

Baseline clinical and procedural variables were stratified by Indigenous status. To control for confounding by preoperative clinical parameters, we used the euroSCORE to model preoperative risk.7 Calibration and discrimination of the euroSCORE in our population were first examined using the c statistic (a measure of concordance) and the Hosmer–Lemeshow goodness-of-fit test. Operative mortality was stratified by Indigenous status in quintiles of the euroSCORE.

Given the marked difference between Indigenous and non-Indigenous people in age of onset of cardiac disease, operative mortality for the entire cohort was first calculated unadjusted, then stratified by age group (< 55 years or ≥ 55 years) and adjusted for euroSCORE as a continuous variable through Cox proportional hazards modelling, after confirming preservation of the proportional hazards assumption. We also tested for interaction between age group, Indigenous status and mortality (operative and late).

For analysis of late mortality, unadjusted Kaplan–Meier survival curves were stratified by age group (< 55 years or ≥ 55 years) and compared by the log-rank test. Adjusted late outcomes in the two groups were compared in patients aged < 55 years using the euroSCORE as a continuous variable as an overall measure of risk in Cox proportional hazard models.

Other in-hospital events were assumed to occur at the time of surgery. These binary events are reported as counts and proportions of the total, and adjusted for euroSCORE and age in logistic regression models. Normally distributed variables are expressed as mean (SD), and non-Gaussian variables as median (interquartile range [IQR]). χ2 tests were used for comparisons of binary outcomes between groups, and t tests for continuous variables. All analyses were performed using Stata software, version 10 (StataCorp, College Station, Tex, USA).

Mortality and in-hospital adverse events in entire cohort

Forty-two patients (1.6%) died either within 30 days of cardiac surgery or during the same admission (Box 3). In the overall cohort, euroSCORE was able to discriminate risk of operative mortality (c statistic, 0.75), but overestimated events in all strata (Hosmer–Lemeshow goodness-of-fit, P < 0.001). The increasing frequency of operative mortality associated with increasing euroSCORE is evident from the graph in Box 4. There was a non-significant trend towards higher operative mortality in Indigenous patients than non-Indigenous patients (2.5% v 1.5%), whether unadjusted or adjusted for euroSCORE (Box 3).

There was no significant excess in new postoperative renal failure (hazard ratio [HR], 1.3 [95% CI, 0.8–2.0]); ventilation time > 24 hours (HR, 1.2 [95% CI, 0.9–1.7]), or postoperative stroke (HR, 0.3 [95% CI, 0.0–2.1]) in the Indigenous group.

At a median follow-up of 45 months (IQR, 25–60 months), there were 293 deaths (11.1%) (Box 3). Indigenous status was associated with a borderline-significant excess in late mortality (Indigenous patients, 12.7% v non-Indigenous patients, 10.9%; HR, 1.4 [95% CI, 0.99–2.0]) that became significant when adjusted for euroSCORE (HR, 1.5 [95% CI, 1.03–2.1]).

Survival at 1 and 5 years was 94.0% and 80.6%, respectively, for Indigenous patients compared with 96.7% and 87.7%, respectively, for non-Indigenous patients (Box 5).

Mortality and in-hospital adverse events in patients under 55 years of age

The mean age of Indigenous patients was substantially lower than the mean age of non-Indigenous patients. When the analysis was restricted to patients aged < 55 years, there was a significant excess in operative mortality among Indigenous patients (Box 6). The difference persisted when adjusted for euroSCORE (Box 3). The operative mortality of Indigenous patients aged < 55 years (3.5%) was in fact higher than that for non-Indigenous patients aged ≥ 55 years (1.7%).

In patients aged < 55 years, at a median follow-up of 45 months, death occurred in 27/202 Indigenous patients (13.4%) and 26/458 non-Indigenous patients (5.7%) (Box 6). Unadjusted survival curves of patients in the two age groups (< 55 years and ≥ 55 years) (Box 7) showed excess late mortality among Indigenous patients compared with non-Indigenous patients in the younger cohort (HR, 3.0 [95% CI, 1.8–5.3]), which persisted despite adjustment for euroSCORE (HR, 6.9 [95% CI, 1.4–33.5]). By contrast, differences in survival between Indigenous and non-Indigenous patients were not significant in the older cohort, whether unadjusted (HR, 1.2 [95% CI, 0.6–2.3]) or adjusted (HR, 0.9 [95% CI, 0.5–1.8) for euroSCORE. This was primarily due to a low number of Indigenous patients (and hence events) in the older age group (interaction P value for age < 55 years, Indigenous status and mortality, 0.005).


Although not statistically significant overall, the difference in operative mortality between Indigenous and non-Indigenous patients was statistically significant in the younger age group (< 55 years). At a median of 45 months’ follow-up, there was an excess in euroSCORE-adjusted mortality in the Indigenous cohort, which again strengthened when restricted to patients under 55 years of age. Adjusting for known predictors of operative and late mortality, Indigenous patients in the younger age group had about seven times greater risk of operative mortality and nearly three times greater risk of late mortality compared with non-Indigenous patients.

The influence of ethnic status on outcomes of cardiac surgery has been described in international settings. In North America, both African-American and South-East Asian populations have been shown to have increased operative mortality after risk adjustment.15-17

Previous studies of Indigenous Australians have focused on the management of valvular disease rather than cardiac surgery overall. They have revealed high rates of morbidity and mortality following valve surgery, particularly after the implantation of mechanical prostheses.18-20 In addition, an excess in age-adjusted mortality after percutaneous mitral commissurotomy has been found in an Indigenous cohort compared with a non-Indigenous control group.20 But, to our knowledge, ours is the first analysis of cardiac surgical outcomes in Indigenous people compared with non-Indigenous people.

Consistent with previous analyses are the differences in baseline characteristics of Indigenous patients presenting with symptomatic cardiovascular disease.18-20 Not only are there significant age differences, but the severity of heart disease appears different. Rheumatic valvular disease and premature coronary atherosclerosis are both major health problems in Indigenous populations and are responsible for the marked age discrepancy in our cohort presenting for cardiac surgery. However, the younger age of onset and severity of heart disease do not completely explain the adverse outcomes, as disparity in outcomes persisted after risk adjustment. Differences in late mortality must also take into account the known higher rate of non-cardiovascular mortality in Indigenous populations.1

Although Indigenous and non-Indigenous patients may not have equal access to sophisticated cardiovascular therapies, our data suggest that cardiovascular mortality in Indigenous patients does not return to that of the overall Australian population even when the most appropriate and effective therapy has been accessed.

A strength of our study was the standardised collection of data and analysis of in-hospital outcomes from a large single-centre registry. A limitation was that, after discharge, the assessment of late outcome was based on total mortality rather than repeated cardiovascular events or need for re-operation. There is some evidence to suggest that differences in the timing of mortality reporting in Indigenous populations have the potential to cause underestimation of mortality at the time of follow-up.1 In addition, we recorded all-cause late mortality rather than death from cardiovascular causes. A larger sample size would allow a more detailed analysis of the mechanisms of adverse outcomes and, potentially, the development of a more accurate operative risk prediction model for Indigenous patients. Future studies should aim at increasing the sample size of Indigenous patients through national collaboration, while maintaining standardised definitions and data collection methods. Although we used the euroSCORE to adjust for surgical risk, the score has not been validated in the Indigenous population. We acknowledge the limitations of using this measure for risk stratification in the Indigenous population, but it is widely used throughout Australia and we believe it to be the best currently available tool for such a purpose.

While improving access of Indigenous Australians to advanced cardiovascular therapies is a major public health priority, improvements in outcomes will require comprehensive strategies that include attention to the primary and secondary prevention of both coronary artery and rheumatic heart disease.

1 Components of the logistic euroSCORE (European System for Cardiac Operative Risk Evaluation)7



Patient-related factors





Chronic pulmonary disease

Long-term use of bronchodilators or steroids for lung disease

Extracardiac arteriopathy

Any one of the following: claudication; carotid occlusion (> 50% stenosis); previous or planned intervention on the abdominal aorta, limb arteries or carotid arteries

Neurological dysfunction disease

Condition severely affecting ambulation or day-to-day functioning

Previous cardiac surgery

Requiring opening of the pericardium

Serum creatinine level

> 200 μmol/L preoperatively

Active endocarditis

Patient still under antibiotic treatment for endocarditis at the time of surgery

Critical preoperative state

Any one or more of the following: ventricular tachycardia or fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before arrival in the anaesthetic room, preoperative inotropic support, intra-aortic balloon counterpulsation or preoperative acute renal failure (anuria or oliguria [< 10mL/hour])

Cardiac-related factors

Unstable angina

Rest angina requiring administration of intravenous nitrates until arrival in the anaesthetic room

Moderate LV dysfunction

LV ejection fraction 30%–50%

Severe LV dysfunction

LV ejection fraction < 30%

Recent myocardial infarct

Within the previous 90 days

Pulmonary hypertension

Systolic pulmonary artery pressure > 60 mmHg

Operation-related factors


Carried out on referral before the beginning of the next working day

Procedure other than isolated CABG

Major cardiac procedure other than or in addition to CABG

Surgery on the thoracic aorta

For disorder of ascending, arch or descending aorta

Post-infarct septal rupture

LV = left ventricular. CABG = coronary artery bypass grafting.

2 Baseline patient data and operative characteristics*


Indigenous patients (n = 283)

Non-Indigenous patients (n = 2352)


Mean age in years (SD)

47 (14)

65 (12)


Female sex

114 (40.3%)

658 (28.0%)

< 0.001


143 (50.5%)

1381 (58.7%)



125 (44.2%)

1545 (65.7%)

< 0.001


112 (39.6%)

643 (27.3%)


Current smoker

102 (36.0%)

299 (12.7%)

< 0.001

Chronic pulmonary disease

15 (5.3%)

160 (6.8%)


Previous cardiac surgery

5 (1.8%)

5 (0.2%)

< 0.001

Serum creatinine level > 200 μmol/L

9 (3.2%)

29 (1.2%)


Unstable angina

19 (6.7%)

281 (11.9%)


Active endocarditis

6 (2.1%)

23 (1.0%)


Pulmonary hypertension

24 (8.5%)

26 (1.1%)

< 0.001

Moderate or severe LV dysfunction

53 (18.7%)

268 (11.4%)

< 0.001

Recent myocardial infarct

50 (17.7%)

447 (19.0%)


Emergency surgery

11 (3.9%)

123 (5.2%)


Median euroSCORE (IQR)

2.08 (1.49–3.92)

2.59 (1.51–5.13)

< 0.001


142 (50.2%)

1790 (76.1%)

< 0.001

Single valve surgery ± CABG

98 (34.6%)

492 (20.9%)

< 0.001

Double valve surgery ± CABG

19 (6.7%)

11 (0.5%)

< 0.001

Other procedures

24 (8.5%)

59 (2.5%)


Mitral valve replacement ± CABG

69 (24.4%)

138 (5.9%)


Implantation of mechanical prosthesis

38 (55.1%)

91 (65.9%)

< 0.001

Mitral valve repair ± CABG

16 (5.7%)

58 (2.5%)

< 0.001

Aortic valve replacement ± CABG

65 (23.0%)

358 (15.2%)


CABG = coronary artery bypass grafting. euroSCORE = European System for Cardiac Operative Risk Evaluation. IQR = interquartile range. LV = left ventricular.
* Values are number (%) of patients, except where otherwise specified.

  • Sam J Lehman1
  • Robert A Baker2
  • Philip E Aylward3
  • John L Knight4
  • Derek P Chew5

  • Department of Cardiology, Flinders University, Adelaide, SA.



Sam Lehman is supported by grants from the National Heart Foundation of Australia, the Cardiac Society of Australia and New Zealand, and the Royal Australian and New Zealand College of Physicians.

Competing interests:

None identified.

  • 1. Australian Bureau of Statistics and Australian Institute of Health and Welfare. The health and welfare of Aboriginal and Torres Straight Islander peoples 2008. Canberra: ABS and AIHW, 2008. (ABS Cat. No. 4704.0; AIHW Cat. No. IHW 21.)
  • 2. Walsh WF. Cardiovascular health in Indigenous Australians: a call for action. Med J Aust 2001; 175: 351-352. <MJA full text>
  • 3. Australian Bureau of Statistics. National Aboriginal and Torres Straight Islander Health Survey, 2004–05. Canberra: ABS, 2006. (ABS Cat. No. 4715.0.)
  • 4. Thompson PL, Bradshaw PJ, Veroni M, et al. Cardiovascular risk among urban Aboriginal people. Med J Aust 2003; 179: 143-146. <MJA full text>
  • 5. Mathur S, Moon L, Leigh S. Aboriginal and Torres Straight Islander people with coronary heart disease: further perspectives on health status and treatment. Canberra: AIHW, 2006. (AIHW Cat. No. CVD 33.)
  • 6. Coory MD, Walsh WF. Rates of percutaneous coronary interventions and bypass surgery after acute myocardial infarction in Indigenous patients. Med J Aust 2005; 182: 507-512. <MJA full text>
  • 7. Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15: 816-822.
  • 8. Nashef SA, Roques F, Hammill BG, et al. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg 2002; 22: 101-105.
  • 9. Michel P, Roques F, Nashef SA; EuroSCORE Project Group. Logistic or additive EuroSCORE for high-risk patients? Eur J Cardiothorac Surg 2003; 23: 684-687.
  • 10. Geissler HJ, Hölzl P, Marohl S, et al. Risk stratification in heart surgery: comparison of six score systems. Eur J Cardiothorac Surg 2000; 17: 400-406.
  • 11. Kawachi Y, Nakashima A, Toshima Y, et al. Risk stratification analysis of operative mortality in heart and thoracic aorta surgery: comparison between Parsonnet and EuroSCORE additive model. Eur J Cardiothorac Surg 2001; 20: 961-966.
  • 12. Gogbashian A, Sedrakyan A, Treasure T. EuroSCORE: a systematic review of international performance. Eur J Cardiothorac Surg 2004; 25: 695-700.
  • 13. Yap CH, Mohajeri M, Ihle BU, et al. Validation of Euroscore model in an Australian patient population. ANZ J Surg 2005; 75: 508-512.
  • 14. Yap CH, Reid C, Yii M, et al. Validation of the EuroSCORE model in Australia. Eur J Cardiothorac Surg 2006; 29: 441-446.
  • 15. Taylor NE, O’Brien S, Edwards FH, et al. Relationship between race and mortality and morbidity after valve replacement surgery. Circulation 2005; 111: 1305-1312.
  • 16. Bridges CR, Edwards FH, Peterson ED, Coombs LP. The effect of race on coronary bypass operative mortality. J Am Coll Cardiol 2000; 36: 1870-1876.
  • 17. Brister SJ, Hamdulay Z, Verma S, et al. Ethnic diversity: South Asian ethnicity is associated with increased coronary artery bypass grafting mortality. J Thorac Cardiovasc Surg 2007; 133: 150-154.
  • 18. Carapetis JR, Powers JR, Currie BJ, et al. Outcomes of cardiac valve replacement for rheumatic heart disease in aboriginal Australians. Asia Pac Heart J 1999; 8: 138-147.
  • 19. McLean A, Waters M, Spencer E, Hadfield C. Experience with cardiac valve operations in Cape York Peninsula and the Torres Strait Islands, Australia. Med J Aust 2007; 186: 560-563. <MJA full text>
  • 20. McCann AB, Walters DL, Aroney CN. Percutaneous balloon mitral commissurotomy in Indigenous versus non-Indigenous Australians. Heart Lung Circ 2008; 17: 200-205.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.